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Biosensors in microarray format provide promising tools for high-throughput analyses of 
complex samples. Although they are able to detect, quantify and characterize a multitude of 
compounds, most of the available devices are specialized in the analysis of one type of 
interaction, limiting their application to a define area. The aim of our work was to develop 
and characterize versatile protein (or peptide) microarrays suitable for the simultaneous 
analysis of a large panel of biological interactions. Our system involved a simple procedure 
to immobilized proteins or peptides, based on pyrrole electropolymerization, and ligand 
binding was detected by imaging the surface plasmon resonance. We demonstrated its 
suitability in three different contexts, i.e. humoral response characterization, ion binding 
analysis and cell detection. This work evidences the potentiality of this approach which 
allows multiparametric, high throughput and label-free analysis of biological samples 
suitable for the detection of compounds as various as proteins, ions or cells and the 
characterization of their interaction with peptides or proteins.  
 





Multiparametric analyses of various 
parameters in a rapid and high-throughput 
way represent a great challenge in many 
domains of application for biology. Since the 
advent of microarrays in the 90s and their 
fruitful use in gene expression monitoring 
(Schena et al. 1995), many efforts were made 
to enlarge their use in other fields than 
genomic. Indeed, their characteristics allow 
high-throughput analysis of small samples 
within a short time together with low-cost 
assays (Howbrook et al. 2003). Nevertheless, 
whereas progress of DNA chips was rapid, 
leading to their wide use and 
commercialisation (Affymetrix), advance of 
other microarrays such as those based on 
protein immobilization was slower. The 
complexity and heterogeneity of proteins, 
along with the necessity to keep their folding 
and their spatial conformation intact after 
binding on the chip surface are certainly 
parameters which have hampered the use of 
proteins in microarrays. In some cases, 
peptide chips are a good alternative to 
protein arrays because the simplicity of the 
structure of such probes confers to them a 
great stability and makes them easier to 
produce. 
Microarray technology involves two 
major steps, i.e. probes immobilization and 
detection of molecular interactions. These 
steps are often related and mostly depend on 
the question which is addressed. Therefore, 
different types of array are needed to 
implement the wide variety of biological 
assays. For example, probes can be directly 
synthesized on the support, but this 
methodology applies only to 
oligonucleotides (Phillips et al. 2008) or 
peptides (Gao et al. 2004). Protein 
attachment can be performed either by 
physical adsorption, or by affinity or 
covalent binding (for review, see Rusmini et 
al. 2007). The passive adsorption leads to 
highly variable binding efficiency depending 
on the molecule since the surface charge of 
proteins is variable and influences their 
interaction with the support (Angenendt et al. 
2003). Moreover, regeneration of the chip 
surface using different solutions (acidic or 
basic pH, high ionic strength) can lead to the 
desorption of the probes, preventing an 
efficient reuse of the chip. Affinity or 
covalent binding requires the presence of 
special groups/molecules on the surface such 
as nitrilotriacetic acid which can react with 
His-tag proteins via Ni2+ ions (Kang et al. 
2007) or streptavidin to retain biotinylated 
probes (Pavlickova and Hug 2004). 
Bifunctional molecules can also be used: one 
functional group allows the binding to the 
surface (via hydroxyl groups present on glass 
for example) and a second group the reaction 
with primary amine groups of proteins 
(MacBeath and Schreiber 2000). However, 
these methods usually imply multi-step 
procedure increasing time and cost for their 
realization and are not always suitable for 
high density probe immobilization. 
Moreover, the process used for biological 
molecule immobilization must be compatible 
with the ensuing detection. Various strategies 
have been developed, most of them involving 
secondary molecules such as antibodies 
and/or labels such as fluorescence dyes (Yu 
et al.). Although these methods allow signal 
amplification and thus have a good 
sensitivity, their applications are thereby 
limited. Furthermore, they provide end-point 
measurements without access to kinetic 
parameters of the binding. Therefore, several 
works emphasize on direct detection 
technologies (for review, see Espina et al. 
2004). Among them, surface plasmon 
resonance (SPR) is an optical method 
allowing the monitoring of biological 
interactions occurring at the surface of 
biosensors. Those consist in glass supports 
layered with a metal film (usually gold) to 
obtain surface plasmon. Advance of SPR 
imaging (SPRi) allows this method to be 
compatible with microarray format for 
multiparametric measurements. This 
approach, first described by Rothenhaüsler 
and Knoll (Rothenhäusler and Knoll 1988) 
and Jordan et al. (Jordan et al. 1997) for 
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DNA chip, was successfully applied to 
peptides, proteins and oligosaccharides 
(Cherif et al. 2006; Kerdiles et al. 2006; 
Uzawa et al. 2008). 
Taking into account that an optimal 
microarray would present advantages for the 
analysis of a large range of biomolecular 
interactions while being easy to realize via a 
single-step procedure, we develop a versatile 
biosensor using SPRi detection associated 
with a simple chemistry to immobilize 
probes (peptides or proteins) such as pyrrole 
electropolymerization (Livache et al. 1994). 
This chemistry allows rapid covalent 
immobilization of different kinds of 
molecules on spatially defined spots. Here, 
we demonstrate the potential of such a 
system offering direct detection of the 
binding of various types of ligands such as 







Bovine serum albumin (BSA) and 
Hen Egg Lysosyme (HEL) were obtained 
from Sigma-Aldrich (St Quentin Fallavier, 
France) and Merck (Paris, France) 
respectively. A97, a polypeptide from 
hepatitis C virus (HCV) Alternate Reading 
Frame Protein (ARFP) (Bain et al. 2004) was 
provided by J.-P. Lavergne. Ni and Co 
binding sites in peptides were determined 
with SVM-prot software 
(http://jing.cz3.nus.edu.sg/cgi-
bin/svmprot.cgi). Pyrrole-protein conjugates 
were generated as described (Kerdiles et al. 
2006). Peptides (Table 1 of supplementary 
data) derived from Ovalbumin (Ova), HCV 
and hepatitis D virus (HDV) were 
synthesized with a pyrrole-modified NH2 
terminus by Altergen, Bischheim, France. 
P12 from tetanus toxin and Poly H (6 His) 
was obtained from Altergen, Bischheim, 
France and pyrrole-poly H conjugates were 
generated as described in (Cherif et al. 2006). 
Monoclonal antibodies (mAb) against mouse 
MHC and CD90, and aspecific Ab used as 
control were purchased from BD Pharmingen 
(Le Pont de Claix, France). Mouse mAb 
against A97 (12F10) (Morice et al. 2009) 
was provided by J.-P. Lavergne. Human 
serums from healthy donors (n=2), HCV-
infected patients (n=4) and HDV-infected 
patients (n=3) were obtained from the 
Etablissement Français du Sang (La Tronche, 
France) and the Centre Hospitalo-
Universitaire (Hepatology and Virology 
services, La Tronche, France). Serums were 




Glass prisms on which a 50 nm gold 
layer was deposited were obtained from 
GenOptics-HORIBA Scientific (Chilly 
Mazarin, France). Electrodeposition  was 
performed using an Omnigrid Micro robotic 
arrayer (GenOptics-HORIBA Scientific, 
Chilly Mazarin, France). SPR signals were 
monitored using a Surface Plasmon 
Resonance imager from GenOptics-HORIBA 
Scientific (Chilly Mazarin, France): for 
antibody binding analyses, we used a SPRi-
Plex apparatus with a 6 µL Teflon chamber 
and for cell or ion binding analyses, we used 
a SPRi-Lab with a 14 µL  Peek chamber, 
connected to a Waters 600E pump 
(Millipore, Lyon, France). 
 
2.3. Cell lines 
 
The murine B lymphocyte cell line 
LS102.9 (ATCC HB-97) was purchased at 
the American Type Culture Collection 
(Rockville, MD, USA). The murine T 
lymphocyte cell line 3A9 was kindly 
provided by C. Rabourdin-Combe 
(INSERM, Lyon, France) (Allen et al. 1985). 
Both cell lines were grown in Dulbecco’s 
modified eagle medium (Gibco, France) 
supplemented with 10 % fetal calf serum 
(FCS), 0.1 mM non essential amino acids, 1 
mM sodium pyruvate, 50 μM 2-
mercaptoethanol, 50 U/mL penicillin and 50 
µg/mL streptomycin. The human 
promyelocytic cell line U937 from the 
American Type Culture Collection 
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(Rockville, MD, USA) (ATCC CRL1593.2) 
was grown in RPMI 1640 supplemented with 
10% FCS, 50 U/mL penicillin and 50 µg/mL 
streptomycin. All cultures were incubated at 
37 °C in a humidified 5% CO2 incubator. 
Before injection of cells onto the chip, Fc 
receptors were blocked by pre-incubating the 
cells for 15min in 15% human serum. 
 
Table 1: Dissociation analysis: slope of the 
dissociation curves obtained after injection of 
serums from two HCV infected patients (SH 
(2) and SH (3)) on a chip grafted with 








C2 -3.09 +/- 0.37 -2.72 +/- 0.58 
E2/3 -0.03 +/- 0.13 -0.00 +/- 0.00 
NS5/2 -1.00 +/- 0.01 -4.92 +/- 0.22 
NS4/7 -4.48 +/- 0.24 -4.62 +/- 0.25 
 
 
2.4. Protein and peptide immobilization on 
gold 
 
Probes were immobilized on the gold 
surface of the chip (80 spots/cm2) by 
electrochemical copolymerization of pyrrole 
with 50 µM (A97 or HEL) or 2µM (mAb) 
pyrrole-proteins conjugates or 100µM 
pyrrole-modified peptides according to 
Cherif et al. 2006. A negative control (Ppy), 
consisting in electropolymerization of 
pyrrole alone was realised. Each probe was 
deposited in triplicate (500 µm diameter 
spots); then, the gold chip was rinsed with 
distilled water and saturated at room 
temperature for 30 min. Saturation solution 
was either 2% (w/v) BSA in phosphate-
buffered saline (PBS = 1.5 mM KH2PO4, 8.1 
mM Na2HPO4, 2.7 mM KCl, 138 mM NaCl, 
pH 7.1) for Ab and ion binding analyses or 
poly(L-Lysine)-PEG (SurfaceSolutionS, 
Zurich, Switzerland) 1mg/mL in PBS for cell 
binding analyses. After saturation, the chip 
was washed with distilled water and placed 
in the SPRi apparatus. 
 
2.5. SPRi interaction monitoring 
 
All reactions were carried out at room 
temperature, in PBS alone or supplemented 
with 0.5 % BSA (w/v) and/or 0.005 % (w/v) 
Tween 20 as indicated in the text. The flow 
rate in the chamber was 37 µL/min (SPRi-
Plex) or 100 µL/min (SPRi-Lab). Ligands 
(ions, Ab or cells) were injected in a volume 
of 500 µL and the biochip surface was rinsed 
to remove unbound ligands. After ion or Ab 
binding, the chip was regenerated by 0.2 M 
imidazole or 0.1 M  HCl-Glycine (pH 2.3) 
respectively for 5min. SPR imaging was 
used to monitor ligand binding, as detailed in 
Cherif et al. 2006. Measurements were 
performed using SPRi dedicated software 




3. Results and discussion 
 
3.1. Qualitative and quantitative analysis of 
Ab in patient serums  
 
Analysis of humoral response upon infection 
and/or after treatment is a challenge for 
diagnosis and prognosis and, most generally, 
to understand the immune response 
mechanisms against pathogens. Whereas 
most of the antigen arrays designed for 
antibody profiling are based on indirect 
method requiring additional labeled partner 
(Bannantine et al. 2008; Li et al. 2008), SPRi 
is an optical method presenting the 
advantage of allowing direct molecular 
interaction measurements without labelling. 
We first evaluated the efficiency of this 
method for the characterization and 
quantification of specific Ab in a microarray 
format. To this end, a polypeptide from HCV 
protein ARFP (A97) was immobilized on a 
gold chip using polypyrrole 
electropolymerization process (cf §2.4) and 
the specific mAb (12F10) raised against this 
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protein was injected. As shown in Fig.1a, 
injection of 12F10 induced an increase in the 
reflectivity signal on spots bearing A97, 
whereas a very low signal was obtained on 
the controls consisting in spots grafted with 
an irrelevant protein (HEL) or with no probe 
(Ppy). This change of reflectivity was 
measured and yielded to a typical binding 
curve (sensorgram, Fig.1b): following an 
initial increase induced by ligand binding 
(association), a decrease of the reflectivity 




Fig. 1. Analysis of Ab binding to peptide 
chip by SPRi: (a) SPR differential image of 
the chip after injection of 12F10 mAb 
(33.3nM) on a peptide chip which was 
grafted with peptide A97. Spots with HEL 
and Ppy alone serve as negative controls. (b) 
Corresponding sensorgrams obtained on 
A97, HEL and Ppy alone spots. (c) 
Correlation between SPRi signal (ΔR) on 
A97 (c) and HEL (y) spots and the amount 
of injected 12F10 mAb after subtraction of 
the background signal (Ppy spots). 
 
 
The dissociation curve corresponds to the 
fast removal of non –specific binding if any 
followed by the dissociation of the surface 
bound-complexes. Thus, Ab binding led to a 
specific signal corresponding to the 
difference between the SPRi signal (ΔR) 
obtained on the positive assay and the 
controls. A regeneration step, consisting in 
the injection of HCl-Glycine pH 2.3, 
eliminated bound mAb to return to the initial 
signal level, thus allowing successive 
injections and measurements. 
Then we evaluated if the SPRi signal 
correlated with the amount of injected mAb. 
Different concentrations of 12F10 mAb were 
successively injected on the chip whose 
surface being regenerated after each assay. 
As shown in Fig.1c, dose-dependent signals 
were obtained on the A97 spot, whereas the 
signal on the control spots remained at a 
background level. In our conditions, we 
could detect mAb binding from a solution 
with a concentration of the order of the 
nanomolar which is the typical limit of 
detection of non amplified SPR-based assays 
(Scarano et al. 2009). 
One important application of this 
method is the analysis of complex Ab 
mixture present in serum for instance from 
patients suffering from infection diseases. 
Determination of the serological specificity 
requires the analysis of numerous potential 
antigens that would benefit from the 
microarray format of our system. Indeed, a 
large number of potential antigens or 
epitopes can be immobilized on the chip (80 
spots) and tested for their reactivity against 
Ab. Viral hepatitis is an interesting model 
since Ab specificities are thought to define a 
signature of the outcome of infection, i.e. 
chronocity, cirrhosis, hepatocarcinoma or 
recovery and of the response to treatment 
(Frangeul et al. 1998; Koshy and Inchauspe 
1996). We designed a chip grafted with 
peptides (~20aa) bearing potential epitopes 
of various regions of the HCV proteins to 
determine by SPRi detection Ab profiles 
from serums of infected patients. Five HCV 
peptides were grafted in triplicate on a chip 
together with a control irrelevant peptide 
(Ova) and serums from healthy (n=2) or 
HCV mono-infected patients (n=4) were  
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Fig. 2. Analysis of humoral response by 
SPRi: (a) Sensorgrams obtained when a 
serum from HCV infected patient was 
injected on a chip which was grafted with 
different HCV peptides and one irrelevant 
peptide as negative control (Ova 74). (b) 
SPRi signal (ΔR) obtained after injection of 
4 serums from HCV infected patients (SH+) 
and 2 from non infected donors (SH-) on a 
chip which was grafted with different HCV 
peptides and with a control peptide (Ova 74). 
(c) SPRi signal obtained after injection of 3 
serums from HDV infected patients (SH+) 
and 2 from non infected donors (SH-) on a 
chip which was grafted with different HDV 
peptides and with a control peptide (Ova 74). 
). This experiment is representative of three 
independent assays. Results are expressed as 
mean value +/- standard deviations obtained 
from spots in triplicate. 
 
 
analyzed. The serum samples were diluted 
(1/50) in PBS, 0.005% (w/v) Tween 20 and 
successively injected with a regeneration step 
between each sample. The reflectivity 
changes measured on each spot were 
recorded simultaneously (Fig.2a) and ΔR 
values were determined from the 
sensorgrams (Fig.2b). The specific signal 
varied according to the tested serums and 
peptides, indicating differences, in terms of 
specificity and amount, in the anti-HCV Ab 
response of the patients. It is important to 
note that similar results were obtained in the 
context of another hepatitis virus infection 
(HDV, Fig.2c), strengthening the fact that 
our system is suitable to establish Ab 
profiles, showing that humoral responses are 
patient-related. 
 
Ab specificity and amount are not the 
only characteristics of a humoral response. 
The interaction parameters, especially the 
dissociation rate constant (koff), are 
indicative for the efficiency of Ab binding. 
As SPRi detection allows label-free and real-
time measurements, it gives access to these 
values. In the case of Ab present in serum, 
some precautions have to be taken: Ab 
elicited by a pathogen can display various 
degree of complexity in term of number of 
specificities. Therefore, the signal obtained 
upon Ab binding on a grafted peptide was 
the resultant of the interactions of different 
Ab. In this case, it is difficult to determine a 
real koff value. Nevertheless, the slope of the 
sensorgram in the dissociation phase (upon 
washing) corresponds to the overall 
dissociation rate. This makes possible 
comparisons between the different serums. 
Thus, as shown in Table I, the dissociation 
rate depends both on the peptides and the 
patient serum. 
Our system allows a rapid, label-free 
characterization of the humoral response 
through the analysis of the specificity, 
amount and dissociation rate of the Ab 
present in serums. This is of great interest for 
diagnosis and prognosis of a wide variety of 
diseases and could be enlarged to screenings 
of various protein- peptide or protein-protein 
interactions such as ligand-receptor, enzyme-
substrate or protein-cofactor interplays. 
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3.2 Ion binding detection by SPRi 
 
Metal ions constitute basic elements 
in many biological systems and is involved 
in a large panel of mechanisms, from 
enzymatic activity to toxicity via oxidative 
mechanisms (Nagase 2001; Beyersmann and 
Hartwig 2008). Identification of proteins 
and/or sequences which interact with metal 
ions as well as detection of these elements in 
fluids are important for fundamental research 
in biology or environmental analysis. The 
versatility of our system prompted us to test 
its suitability for the detection of metal ion 
binding. Three peptides were chosen as 
probes, one consisting in a poly-H sequence 
known to interact with ions such as Ni2+ 
(Paborsky et al. 1996), another from tetanus 
toxin (P12), which includes two His and was 
described as interacting slightly with Ni2+ 
(Villiers et al. 1993) and the last one 
corresponding to an HCV sequence (NS4/7) 
devoid of Ni binding site. These peptides 
were grafted on a gold chip using 
polypyrrole electropolymerization process 
(cf §2.4) and different concentrations of 
NiSO4 were injected. Regeneration between 
each injection was performed using 0.2M 
imidazole. As shown in Fig.3a, a specific 
signal was observed on the poly-H spot 
whereas only weak signal was detected on 
the control spots (NS4/7 peptide and Ppy 
alone). The decrease in the number of His 
residues in the tested peptide (P12) strongly 
reduced Ni2+ binding. The specificity of the 
system was also assessed by injecting CoCl2: 
as expected, no specific binding was 
observed on the tested peptides. Moreover, a 
very good correlation was obtained between 
the SPRi signal and the concentration of the 
injected Ni2+ (Fig.3b). It is usually assumed 
that SPRi signal results from a change in the 
refractive index near the gold surface caused 
by an increase in mass at the metal surface 
(Williams and Addona 2000). If it is the case 
for the binding of large ligands such as 
proteins or cells, another phenomenon is 
probably involved in the case of ion binding 
since the global increase in the mass is very 
 
 
Fig. 3. Analysis of ion binding to peptide 
chip by SPRi: (a) SPRi signal obtained after 
injection of different concentrations of Ni2+ 
on a chip bearing poly-His, NS4/7 peptide 
and Ppy alone. (b) Correlation between 
specific SPRi signal (ΔR) on poly-His spots 
and the amount of injected Ni2+ after 
subtraction of the background signal (Ppy 
spots). This experiment is representative of 
three independent assays. Results are 
expressed as mean value +/- standard 
deviations obtained from spots in triplicate. 
 
 
weak. Moreover, an influence of the metal 
ion “per se” is unlikely as the refractive 
index of the metal solution, within the 
concentration range tested, was similar to 
that of the running buffer. It seems likely that 
SPR signal is generated by a 
conformational change of the peptide 
induced by ion binding which modifies the 
structure of the peptide inducing a change in 
the mass gradient on the gold surface. 
Indeed, protein/peptide structure is known to 
change upon the binding of ligands, 
especially metal ions (Ivanova et al. 2008; 
Tougu et al. 2008). Nevertheless, the 
conformational change of the peptide may be 
not sufficient to account for the increase in 
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SPR signal. Our data and previous ones 
(Palumbo et al. 2005; Palumbo et al. 2003) 
suggest an interference of the metal ion with 
the resonance phenomenon leading to an 
increase in the SPR signal. Although SPR 
has already been used for metal ion 
detection, our system differs from previously 
described ones (Forzani et al. 2005; Zhang et 
al. 2007), in associating SPR imaging to 
immobilization of the peptides in multiple 
spatially defined positions that supports 
multiparametric measurements. Thus, 
immobilization of different peptides, selected 
for their specific interaction with different 
metal ions, would allow high throughput 
analyses of peptide-metal ion interactions or 
metal ion content of a fluid. 
 
3.3. Biosensor-based cell capture and SPRi 
detection  
 
The different characteristics of our 
system (ease of manufacture of 
peptide/protein chips, high throughput, label-
free, real-time detection) prompted us to 
adapt the method for the specific capture and 
detection of discrete cells. The detection of 
sparse cells in biological samples is a 
frequent need in both biological and medical 
research. Samples issued from clinics are 
generally either blood cells or tissues from 
biopsies or surgery, where cells of interest 
are mixed with other cells of the donors. 
Although methods exist to identify discrete 
cells in complex samples, they require 
usually relatively large amounts of cells. 
Microsystems offer the possibility to analyze 
samples of a reduced size and therefore could 
contribute to the establishment of less 
invasive samplings. Several methods are 
currently used, based on nucleic acid 
sequence detection or on cell labeling and 
often require enrichment (Blumke et al. 
2005; Pantel and von Knebel Doeberitz 
2000). In order to develop a sensitive and 
discriminative method to directly detect cells 
in a mixed population, we immobilized on 
the chip surface Ab directed against cell 
surface markers. The cells injected on the 
chip were mouse T lymphocytes (3A9 cell 
line) together with mock cells consisting in 
U937, a human promyelocytic line. Different 
3A9/U937 ratios (from 0% to 80%) were 
injected with a total cell number equal to 
300,000 cells. The different injections were 
realized successively, without chip 
regeneration which is unachievable probably 
owing to multiple-point binding between 
cells and Ab. Thus, the measurements after 
each injection correspond to cumulated 
signal. Anti-CD90 mAb was used as T 
lymphocyte-specific Ab and we used a non 
specific IgG as negative control. As shown in 
Fig.4a, cell binding to immobilized mAb 
induced changes in the reflectivity: the signal 
increased with the number of injected T 
lymphocytes and was highly specific, since 
only a weak signal was obtained on the 
control spot and when U937 cells were 
injected alone. The specificity of the system 
was also assessed by injecting another cell 
type (B lymphocyte cell line LS102.9) on a 
chip bearing anti-CD90 mAb (T lymphocyte 
specific) and a mAb against a molecule 
present on B but not on T lymphocytes (anti-
MHC). Results were compared to those 
obtained upon T lymphocyte injection. As 
shown in Fig.4b, whereas T cells bound only 
on anti-CD90 spots, B cells interact only 
with anti-MHC spot. In both cases, only a 
weak signal was observed on the control spot 
(unspecific IgG). These results confirmed the 
high specificity of the cell-Ab interactions 




The combination of a chip bearing 
peptides or proteins immobilized in a 
microarray format with SPR imaging 
provides a unique system which allows the 
detection of a large panel of ligands such as 
ions, proteins and cells. This method presents 
several advantages for label-free, 
multiparametric and real time analysis. The 
challenge consists in the design of probes 
allowing, by itself or in combination, 
discrimination between different ligands. The 
possibility of reducing the spot size to 5-
10µm diameter (Roupioz et al. 2009) allows 
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the design of high-density microarrays for 
high-throughput analysis.  
 
 
Fig. 4. Analysis of cell binding to Ab chip by 
SPRi: (a) SPRi signal (ΔR) obtained after 
successive injections of T lymphocytes 
(3A9) mixed with U937 in different ratios 
(3x105 total cells) on a chip bearing mAb 
anti-CD90 (c) and IgG control (). (b) SPRi 
signal (ΔR) obtained on spots bearing mAb 
anti-CD90, anti-MHC and IgG control upon 
one injection of 5x105 cells (B or T 
lymphocytes) after subtraction of the 
background signal. Each experiment is 
representative of three independent assays. 
Results are expressed as mean value +/- 




Furthermore, precise localisation of the spots 
offers the possibility to obtain complex 
designs of the surface suitable for the 
quantification of several entities of different 
nature (ions, proteins, cells) in a single 
format. The same type of fluidic system can 
be used in all cases as the Peek chamber 
described for cell and ion detection is 
suitable for proteins (data not shown) 
although requiring a larger sample volume. 
Whatever the type of ligand tested, the 
sensitivity of our method is similar to what it 
is usually obtained with label-free biosensors 
(10-9M for Ab (Labib et al. 2009), 10-5M for 
ions (Palumbo et al. 2005), 104 /mL for cells 
(Ishikawa et al. 2009). 
The versatility of this system makes 
this technology a powerful tool which could 
be integrated in several domains such as 
clinical applications for the detection of 
biological markers, for basic research to 
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Table 1: Sequences of peptides used in this study 
 
 
Origin Peptide Sequence 
C2 KTKRNTNRRPQDVKFPGGGQ 











TETANUS TOXIN P12 ELIHVLHGLYGMQVSS 
Ovalbumin Ova 74 GTSVNVHSSLRDILNQITKPND 
 
 
 
 
 
 
